{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:41:03Z","timestamp":1759416063489,"version":"build-2065373602"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2019A1515011786"],"award-info":[{"award-number":["2019A1515011786"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural science foundation of China","doi-asserted-by":"crossref","award":["82172711"],"award-info":[{"award-number":["82172711"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02437-0","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:33:00Z","timestamp":1759408380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yunxin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxin","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2437_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2437_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in china, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"2437_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, et al. Five-Year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial. JAMA Oncol. 2022;8:1571\u20138.","journal-title":"JAMA Oncol"},{"key":"2437_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2437_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:439\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"2437_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"2437_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"2437_CR8","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, Dean A, Kiss I, Lee WJ, Goetze TO, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"key":"2437_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et al. Nanoliposomal Irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357.","journal-title":"Lancet"},{"key":"2437_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12885-020-06945-8","volume":"20","author":"M Sawada","year":"2020","unstructured":"Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, Yamada Y, Takeda T, Kanata R, Matsuyama M, et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer. 2020;20:449.","journal-title":"BMC Cancer"},{"key":"2437_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al. Maintenance Olaparib for germline BRCA-Mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"2437_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"2437_CR13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437\u201348.","journal-title":"Lancet Oncol"},{"key":"2437_CR14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Papai Z, et al. Trifluridine-Tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367.","journal-title":"N Engl J Med"},{"key":"2437_CR15","first-page":"571","volume":"25","author":"T Emura","year":"2004","unstructured":"Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004;25:571\u20138.","journal-title":"Int J Oncol"},{"key":"2437_CR16","doi-asserted-by":"crossref","unstructured":"Wang X, Li Z, Sha D, Ren H, Yi C, Li S, Wang P, Chu Y, Li C, Shan G et al. Efficacy and safety of regorafenib plus biweekly trifluridine\/tipiracil for refractory metastatic colorectal cancer: a multicenter single-arm phase II trial. Oncologist. 2025;30:oyaf129.","DOI":"10.1093\/oncolo\/oyaf129"},{"key":"2437_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40265-021-01489-y","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Surufatinib: first approval. Drugs. 2021;81:727\u201332.","journal-title":"Drugs"},{"key":"2437_CR18","doi-asserted-by":"publisher","first-page":"122838","DOI":"10.1016\/j.biomaterials.2024.122838","volume":"314","author":"S Tabe","year":"2025","unstructured":"Tabe S, Takeuchi K, Aoshima K, Okumura A, Yamamoto Y, Yanagisawa K, Eto R, Matsuo M, Ueno Y, Konishi T, et al. A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival. Biomaterials. 2025;314:122838.","journal-title":"Biomaterials"},{"key":"2437_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00262-024-03677-7","volume":"73","author":"P Zhang","year":"2024","unstructured":"Zhang P, Chen Z, Shi S, Li Z, Ye F, Song L, Zhang Y, Yin F, Zhang X, Xu J, et al. Efficacy and safety of Surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric\/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer. Cancer Immunol Immunother. 2024;73:119.","journal-title":"Cancer Immunol Immunother"},{"key":"2437_CR20","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, Krug K, Clark DJ, Schnaubelt M, Chen L, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184:5031\u2013e50525026.","journal-title":"Cell"},{"key":"2437_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-023-02790-x","volume":"30","author":"L Jiang","year":"2024","unstructured":"Jiang L, Qin J, Dai Y, Zhao S, Zhan Q, Cui P, Ren L, Wang X, Zhang R, Gao C, et al. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Nat Med. 2024;30:749\u201361.","journal-title":"Nat Med"},{"key":"2437_CR22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41586-024-08225-y","volume":"637","author":"P Huang","year":"2025","unstructured":"Huang P, Gao W, Fu C, Wang M, Li Y, Chu B, He A, Li Y, Deng X, Zhang Y, et al. Clinical functional proteomics of intercellular signalling in pancreatic cancer. Nature. 2025;637:726\u201335.","journal-title":"Nature"},{"key":"2437_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/jjco\/hyab091","volume":"51","author":"T Mie","year":"2021","unstructured":"Mie T, Sasaki T, Takeda T, Okamoto T, Mori C, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Jpn J Clin Oncol. 2021;51:1416\u201322.","journal-title":"Jpn J Clin Oncol"},{"key":"2437_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-023-11464-3","volume":"23","author":"H Tang","year":"2023","unstructured":"Tang H, Ge Y, You T, Li X, Wang Y, Cheng Y, Bai C. A real-world analysis of Trametinib in combination with hydroxychloroquine or CDK4\/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma. BMC Cancer. 2023;23:958.","journal-title":"BMC Cancer"},{"key":"2437_CR25","doi-asserted-by":"publisher","first-page":"102544","DOI":"10.1016\/j.redox.2022.102544","volume":"58","author":"T Tian","year":"2022","unstructured":"Tian T, Lu Y, Lin J, Chen M, Qiu H, Zhu W, Sun H, Huang J, Yang H, Deng W. CPT1A promotes Anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis. Redox Biol. 2022;58:102544.","journal-title":"Redox Biol"},{"key":"2437_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","volume":"14","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang ZX, Chen YX, Wu HX, Yin L, Zhao Q, Luo HY, Zeng ZL, Qiu MZ, Xu RH. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022;14:45.","journal-title":"Genome Med"},{"key":"2437_CR27","doi-asserted-by":"publisher","first-page":"148735","DOI":"10.1016\/j.gene.2024.148735","volume":"927","author":"YF Yin","year":"2024","unstructured":"Yin YF, Jia QY, Yao HF, Zhu YH, Zheng JH, Duan ZH, Hu CY, Sun YW, Liu DJ, Huo YM, Liu W. OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway. Gene. 2024;927:148735.","journal-title":"Gene"},{"key":"2437_CR28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12885-024-12016-z","volume":"24","author":"A Gueiderikh","year":"2024","unstructured":"Gueiderikh A, Tarabay A, Abdelouahab M, Smolenschi C, Tanguy ML, Valery M, Malka D, Pudlarz T, Fuerea A, Boige V, et al. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. BMC Cancer. 2024;24:272.","journal-title":"BMC Cancer"},{"key":"2437_CR29","doi-asserted-by":"publisher","first-page":"1251258","DOI":"10.3389\/fonc.2023.1251258","volume":"13","author":"HR Lu","year":"2023","unstructured":"Lu HR, Zhu PF, Deng YY, Chen ZL, Yang L. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study. Front Oncol. 2023;13:1251258.","journal-title":"Front Oncol"},{"key":"2437_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.21037\/jgo-22-632","volume":"14","author":"C Mohring","year":"2023","unstructured":"Mohring C, Frontado Graffe FJ, Bartels A, Sadeghlar F, Zhou T, Mahn R, Marinova M, Feldmann G, Brossart P, Glowka TR, et al. Second-line and third-line therapy with nanoliposomal Irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature. J Gastrointest Oncol. 2023;14:352\u201365.","journal-title":"J Gastrointest Oncol"},{"key":"2437_CR31","doi-asserted-by":"publisher","first-page":"175883592413098","DOI":"10.1177\/17588359241309828","volume":"17","author":"R Alvarez-Gallego","year":"2025","unstructured":"Alvarez-Gallego R, Pazo-Cid R, Lopez de San Vicente B, Macarulla T, Martinez E, Garicano F, Hernandez I, Granja M, Ghanem I, Martinez J, et al. Real-world effectiveness and safety of second- or third-line pegylated liposomal Irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain. Ther Adv Med Oncol. 2025;17:17588359241309828.","journal-title":"Ther Adv Med Oncol"},{"key":"2437_CR32","doi-asserted-by":"publisher","first-page":"20353","DOI":"10.1002\/cam4.6621","volume":"12","author":"EG Chiorean","year":"2023","unstructured":"Chiorean EG, Picozzi V, Li CP, Peeters M, Maurel J, Singh J, Golan T, Blanc JF, Chapman SC, Hussain AM, et al. Efficacy and safety of abemaciclib alone and with PI3K\/mTOR inhibitor LY3023414 or Galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial. Cancer Med. 2023;12:20353\u201364.","journal-title":"Cancer Med"},{"key":"2437_CR33","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1200\/JCO.21.02511","volume":"40","author":"IM Chen","year":"2022","unstructured":"Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, Hasselby JP, Willemoe GL, Lorentzen T, Madsen K, et al. Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). J Clin Oncol. 2022;40:3180\u20139.","journal-title":"J Clin Oncol"},{"key":"2437_CR34","doi-asserted-by":"publisher","first-page":"e073995","DOI":"10.1136\/bmj-2022-073995","volume":"383","author":"M Del Chiaro","year":"2023","unstructured":"Del Chiaro M, Sugawara T, Karam SD, Messersmith WA. Advances in the management of pancreatic cancer. BMJ. 2023;383:e073995.","journal-title":"BMJ"},{"key":"2437_CR35","doi-asserted-by":"publisher","first-page":"113950","DOI":"10.1016\/j.ejca.2024.113950","volume":"201","author":"T Enzler","year":"2024","unstructured":"Enzler T, Nguyen A, Misleh J, Cline VJ, Johns M, Shumway N, Paulson S, Siegel R, Larson T, Messersmith W, et al. A multicenter, randomized phase 2 study to Establish combinations of CBP501, cisplatin and nivolumab for >\/=3rd-line treatment of patients with advanced pancreatic adenocarcinoma. Eur J Cancer. 2024;201:113950.","journal-title":"Eur J Cancer"},{"key":"2437_CR36","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Gorner M, Molle M, Greten TF, Lakner V, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423\u20139.","journal-title":"J Clin Oncol"},{"key":"2437_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"2437_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/gutjnl-2021-325564","volume":"72","author":"M Alonso-Nocelo","year":"2023","unstructured":"Alonso-Nocelo M, Ruiz-Canas L, Sancho P, Gorgulu K, Alcala S, Pedrero C, Vallespinos M, Lopez-Gil JC, Ochando M, Garcia-Garcia E, et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut. 2023;72:345\u201359.","journal-title":"Gut"},{"key":"2437_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1440-1827.2012.02825.x","volume":"62","author":"C Nagata","year":"2012","unstructured":"Nagata C, Kobayashi H, Sakata A, Satomi K, Minami Y, Morishita Y, Ohara R, Yoshikawa H, Arai Y, Nishida M, Noguchi M. Increased expression of OCIA domain containing 2 during Stepwise progression of ovarian mucinous tumor. Pathol Int. 2012;62:471\u20136.","journal-title":"Pathol Int"},{"key":"2437_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/cyt.12220","volume":"26","author":"N Itoguchi","year":"2015","unstructured":"Itoguchi N, Nakagawa T, Murata Y, Li D, Shiba-Ishii A, Minami Y, Noguchi M. Immunocytochemical staining for stratifin and OCIAD2 in bronchial washing specimens increases sensitivity for diagnosis of lung cancer. Cytopathology. 2015;26:354\u201361.","journal-title":"Cytopathology"},{"key":"2437_CR41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/carcin\/bgx073","volume":"38","author":"D Wu","year":"2017","unstructured":"Wu D, Yang X, Peng H, Guo D, Zhao W, Zhao C, Zhou X. OCIAD2 suppressed tumor growth and invasion via AKT pathway in hepatocelluar carcinoma. Carcinogenesis. 2017;38:910\u20139.","journal-title":"Carcinogenesis"},{"key":"2437_CR42","doi-asserted-by":"publisher","first-page":"ar29","DOI":"10.1091\/mbc.E21-03-0143","volume":"33","author":"KJ Chojnacka","year":"2022","unstructured":"Chojnacka KJ, Elancheliyan P, Mussulini BHM, Mohanraj K, Callegari S, Gosk A, Banach T, Goral T, Szczepanowska K, Rehling P, et al. Ovarian carcinoma immunoreactive antigen-like protein 2 (OCIAD2) is a novel complex III-specific assembly factor in mitochondria. Mol Biol Cell. 2022;33:ar29.","journal-title":"Mol Biol Cell"},{"key":"2437_CR43","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, et al. Chemotherapy-Resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716\u201335.","journal-title":"Cancer Discov"},{"key":"2437_CR44","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.stem.2013.04.006","volume":"12","author":"KB Myant","year":"2013","unstructured":"Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, Schwitalla S, Kalna G, Ogg EL, Athineos D, et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013;12:761\u201373.","journal-title":"Cell Stem Cell"},{"key":"2437_CR45","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cmet.2015.08.015","volume":"22","author":"P Sancho","year":"2015","unstructured":"Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M, Barneda D, Sellers K, Campos-Olivas R, Grana O, et al. MYC\/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 2015;22:590\u2013605.","journal-title":"Cell Metab"},{"key":"2437_CR46","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1038\/s41467-020-18954-z","volume":"11","author":"S Valle","year":"2020","unstructured":"Valle S, Alcala S, Martin-Hijano L, Cabezas-Sainz P, Navarro D, Munoz ER, Yuste L, Tiwary K, Walter K, Ruiz-Canas L, et al. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Nat Commun. 2020;11:5265.","journal-title":"Nat Commun"},{"key":"2437_CR47","doi-asserted-by":"crossref","unstructured":"Ferrara B, Dugnani E, Sordi V, Pasquale V, Pellegrini S, Reni M, Balzano G, Piemonti L. A comprehensive characterization of stemness in cell lines and primary cells of pancreatic ductal adenocarcinoma. Int J Mol Sci. 2022;23:10663.","DOI":"10.3390\/ijms231810663"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02437-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:03:44Z","timestamp":1759413824000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02437-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02437-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"type":"electronic","value":"1476-4598"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and related documentation were approved by the Ethics Committee of Sun Yat-sen University Cancer Center and conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice (GCP). Written informed consent was obtained from all enrolled patients. All authors had access to the study data and reviewed and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}